References
- Barentsz JO, Richenberg J, Clements R, Choyke P, Verma S, Villeirs G, et al. ESUR prostate MR guidelines 2012. Eur Radiol 2012;22:746-757 https://doi.org/10.1007/s00330-011-2377-y
- Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med 2018;378:1767-1777 https://doi.org/10.1056/NEJMoa1801993
- Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet 2017;389:815-822 https://doi.org/10.1016/S0140-6736(16)32401-1
- Kasivisvanathan V, Stabile A, Neves JB, Giganti F, Valerio M, Shanmugabavan Y, et al. Magnetic resonance imaging-targeted biopsy versus systematic biopsy in the detection of prostate cancer: a systematic review and meta-analysis. Eur Urol 2019;76:284-303 https://doi.org/10.1016/j.eururo.2019.04.043
- Welty CJ, Cowan JE, Nguyen H, Shinohara K, Perez N, Greene KL, et al. Extended followup and risk factors for disease reclassification in a large active surveillance cohort for localized prostate cancer. J Urol 2015;193:807-811 https://doi.org/10.1016/j.juro.2014.09.094
- Alberts AR, Roobol MJ, Drost FH, van Leenders GJ, Bokhorst LP, Bangma CH, et al. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer. BJU Int 2017;120:511-519 https://doi.org/10.1111/bju.13836
- Klotz L, Loblaw A, Sugar L, Moussa M, Berman DM, Van der Kwast T, et al. Active surveillance magnetic resonance imaging study (ASIST): results of a randomized multicenter prospective trial. Eur Urol 2018;75:300-309 https://doi.org/10.1016/j.eururo.2018.06.025
- Nahar B, Katims A, Barboza MP, Soodana Prakash N, Venkatramani V, Kava B, et al. Reclassification rates of patients eligible for active surveillance after the addition of magnetic resonance imaging-ultrasound fusion biopsy: an analysis of 7 widely used eligibility criteria. Urology 2017;110:134-139 https://doi.org/10.1016/j.urology.2017.08.016
- Kimura M, Tay KJ, Muto S, Horie S. Focal therapy and active surveillance of prostate cancer in East and Southeast Asia. In: Polascik T, ed. Imaging and focal therapy of early prostate cancer, 2nd ed. New York: Springer, 2017:75-81
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424 https://doi.org/10.3322/caac.21492
- Zhang K, Bangma CH, Roobol MJ. Prostate cancer screening in Europe and Asia. Asian J Urol 2017;4:86-95 https://doi.org/10.1016/j.ajur.2016.08.010
- Peyromaure M, Debre B, Mao K, Zhang G, Wang Y, Sun Z, et al. Management of prostate cancer in China: a multicenter report of 6 institutions. J Urol 2005;174:1794-1797 https://doi.org/10.1097/01.ju.0000176817.46279.93
- Tosoian JJ, JohnBull E, Trock BJ, Landis P, Epstein JI, Partin AW, et al. Pathological outcomes in men with low risk and very low risk prostate cancer: implications on the practice of active surveillance. J Urol 2013;190:1218-1222 https://doi.org/10.1016/j.juro.2013.04.071
- Parker PA, Davis JW, Latini DM, Baum G, Wang X, Ward JF, et al. Relationship between illness uncertainty, anxiety, fear of progression and quality of life in men with favourable-risk prostate cancer undergoing active surveillance. BJU Int 2015;117:469-477 https://doi.org/10.1111/bju.13099
- Zhu Y, Freedland SJ, Ye D. Prostate cancer and prostatic diseases best of Asia, 2019: challenges and opportunities. Prostate Cancer Prostatic Dis 2020;23:197-198 https://doi.org/10.1038/s41391-019-0193-7
- Mochtar CA, Andika RS. The value of prostate-specific antigen in Asia. Ther Adv Urol 2010;2:77-83 https://doi.org/10.1177/1756287210370329
- Komisarenko M, Martin LJ, Finelli A. Active surveillance review: contemporary selection criteria, follow-up, compliance and outcomes. Transl Androl Urol 2018;7:243-255 https://doi.org/10.21037/tau.2018.03.02
- Dall'Era MA, Konety BR, Cowan JE, Shinohara K, Stauf F, Cooperberg MR, et al. Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer 2008;112:2664-2670 https://doi.org/10.1002/cncr.23502
- Bayar G, Horasanli K, Acinikli H, Tanriverdi O, Dalkilic A, Arisan S. The importance of active surveillance, and immediate re-biopsy in low-risk prostate cancer: the largest series from Turkey. Turk J Urol 2016;42:140-144 https://doi.org/10.5152/tud.2016.47786
- Ercole B, Parekh DJ. Active surveillance: pitfalls to consider. Arch Esp Urol 2011;64:695-702
- Kalapara AA, Verbeek JFM, Nieboer D, Fahey M, Gnanapragasam V, Van Hemelrijck M, et al. Adherence to active surveillance protocols for low-risk prostate cancer: results of the Movember foundation's global action plan prostate cancer active surveillance initiative. Eur Urol Oncol 2020;3:80-91 https://doi.org/10.1016/j.euo.2019.08.014
- Jin BS, Kang SH, Kim DY, Oh HG, Kim CI, Moon GH, et al. Pathological upgrading in prostate cancer patients eligible for active surveillance: does prostate-specific antigen density matter? Korean J Urol 2015;56:624-629 https://doi.org/10.4111/kju.2015.56.9.624
- Tay KJ, Mendez M, Moul JW, Polascik TJ. Active surveillance for prostate cancer: can we modernize contemporary protocols to improve patient selection and outcomes in the focal therapy era? Curr Opin Urol 2015;25:185-190 https://doi.org/10.1097/MOU.0000000000000168
- Rouviere O, Moldovan PC. The current role of prostate multiparametric magnetic resonance imaging. Asian J Urol 2019;6:137-145 https://doi.org/10.1016/j.ajur.2018.12.001
- Richenberg J, Logager V, Panebianco V, Rouviere O, Villeirs G, Schoots IG. The primacy of multiparametric MRI in men with suspected prostate cancer. Eur Radiol 2019;29:6940-6952 https://doi.org/10.1007/s00330-019-06166-z
- Padhani AR, Barentsz J, Villeirs G, Rosenkrantz AB, Margolis DJ, Turkbey B, et al. PI-RADS steering committee: the PI-RADS multiparametric MRI and MRI-directed biopsy pathway. Radiology 2019;292:464-474 https://doi.org/10.1148/radiol.2019182946
- Borofsky S, George AK, Gaur S, Bernardo M, Greer MD, Mertan FV, et al. What are we missing? False-negative cancers at multiparametric MR imaging of the prostate. Radiology 2018;286:186-195 https://doi.org/10.1148/radiol.2017152877
- Schoots IG, Nieboer D, Giganti F, Moore CM, Bangma CH, Roobol MJ. Is magnetic resonance imaging-targeted biopsy a useful addition to systematic confirmatory biopsy in men on active surveillance for low-risk prostate cancer? A systematic review and meta-analysis. BJU Int 2018;122:946-958 https://doi.org/10.1111/bju.14358
- Park BH, Jeon HG, Choo SH, Jeong BC, Seo SI, Jeon SS, et al. Role of multiparametric 3.0-Tesla magnetic resonance imaging in patients with prostate cancer eligible for active surveillance. BJU Int 2014;113:864-870 https://doi.org/10.1111/bju.12423
- Park JJ, Park BK. Role of PI-RADSv2 with multiparametric MRI in determining who needs active surveillance or definitive treatment according to PRIAS. J Magn Reson Imaging 2017;45:1753-1759 https://doi.org/10.1002/jmri.25534
- Turkbey B, Mani H, Aras O, Ho J, Hoang A, Rastinehad AR, et al. Prostate cancer: can multiparametric MR imaging help identify patients who are candidates for active surveillance? Radiology 2013;268:144-152 https://doi.org/10.1148/radiol.13121325
- Tay KJ, Gupta RT, Holtz J, Silverman RK, Tsivian E, Schulman A, et al. Does mpMRI improve clinical criteria in selecting men with prostate cancer for active surveillance? Prostate Cancer Prostatic Dis 2017;20:323-327 https://doi.org/10.1038/pcan.2017.20
- Stamatakis L, Siddiqui MM, Nix JW, Logan J, Rais-Bahrami S, Walton-Diaz A, et al. Accuracy of multiparametric magnetic resonance imaging in confirming eligibility for active surveillance for men with prostate cancer. Cancer 2013;119:3359-3366 https://doi.org/10.1002/cncr.28216
- National Insitute of Health and Care Excellence. Prostate cancer: diagnosis and management (NICE guideline 131). Nice.org.uk Web site. https://www.nice.org.uk/guidance/ng131. Published May 9, 2019. Accessed September 4, 2020
- Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 2017;71:618-629 https://doi.org/10.1016/j.eururo.2016.08.003
- Yoo S, Hong JH, Byun SS, Lee JY, Chung BH, Kim CS. Is suspicious upstaging on multiparametric magnetic resonance imaging useful in improving the reliability of Prostate Cancer Research International Active Surveillance (PRIAS) criteria? Use of the K-CaP registry. Urol Oncol 2017;35:459.e7-459.e13 https://doi.org/10.1016/j.urolonc.2016.07.014
- Thurtle D, Barrett T, Thankappan-Nair V, Koo B, Warren A, Kastner C, et al. Progression and treatment rates using an active surveillance protocol incorporating image-guided baseline biopsies and multiparametric magnetic resonance imaging monitoring for men with favourable-risk prostate cancer. BJU Int 2018;122:59-65 https://doi.org/10.1111/bju.14166
- Eineluoto JT, Jarvinen P, Kenttamies A, Kilpelainen TP, Vasarainen H, Sandeman K, et al. Repeat multiparametric MRI in prostate cancer patients on active surveillance. PLoS One 2017;12:e0189272
- Perlis N, Al-Kasab T, Ahmad A, Goldberg E, Fadak K, Sayyid R, et al. Defining a cohort that may not require repeat prostate biopsy based on PCA3 score and magnetic resonance imaging: the dual negative effect. J Urol 2018;199:1182-1187 https://doi.org/10.1016/j.juro.2017.11.074
- Felker ER, Wu J, Natarajan S, Margolis DJ, Raman SS, Huang J, et al. Serial magnetic resonance imaging in active surveillance of prostate cancer: incremental value. J Urol 2016;195:1421-1427 https://doi.org/10.1016/j.juro.2015.11.055
- Walton Diaz A, Shakir NA, George AK, Rais-Bahrami S, Turkbey B, Rothwax JT, et al. Use of serial multiparametric magnetic resonance imaging in the management of patients with prostate cancer on active surveillance. Urol Oncol 2015;33:202.e1-202.e7 https://doi.org/10.1016/j.urolonc.2015.01.023
- Hamoen EHJ, Hoeks CMA, Somford DM, van Oort IM, Vergunst H, Oddens JR, et al. Value of serial multiparametric magnetic resonance imaging and magnetic resonance imaging-guided biopsies in men with low-risk prostate cancer on active surveillance after 1 yr follow-up. Eur Urol Focus 2019;5:407-415 https://doi.org/10.1016/j.euf.2017.12.008
- Klotz L, Pond G, Loblaw A, Sugar L, Moussa M, Berman D, et al. Randomized study of systematic biopsy versus magnetic resonance imaging and targeted and systematic biopsy in men on active surveillance (ASIST): 2-year postbiopsy follow-up. Eur Urol 2020;77:311-317 https://doi.org/10.1016/j.eururo.2019.10.007
- Glass AS, Dall'Era MA. Use of multiparametric magnetic resonance imaging in prostate cancer active surveillance. BJU Int 2019;124:730-737 https://doi.org/10.1111/bju.14705
- Stavrinides V, Giganti F, Emberton M, Moore CM. MRI in active surveillance: a critical review. Prostate Cancer Prostatic Dis 2019;22:5-15 https://doi.org/10.1038/s41391-018-0077-2
- Sanda MG, Cadeddu JA, Kirkby E, Chen RC, Crispino T, Fontanarosa J, et al. Clinically localized prostate cancer: AUA/ASTRO/SUO guideline. Part I: risk stratification, shared decision making, and care options. J Urol 2018;199:683-690 https://doi.org/10.1016/j.juro.2017.11.095
- Morash C, Tey R, Agbassi C, Klotz L, McGowan T, Srigley J, et al. Active surveillance for the management of localized prostate cancer: guideline recommendations. Can Urol Assoc J 2015;9:171-178 https://doi.org/10.5489/cuaj.2806
- Stavrinides V, Giganti F, Trock B, Punwani S, Allen C, Kirkham A, et al. Five-year outcomes of magnetic resonance imaging-based active surveillance for prostate cancer: a large cohort study. Eur Urol 2020;78:443-451 https://doi.org/10.1016/j.eururo.2020.03.035
- Gallagher KM, Christopher E, Cameron AJ, Little S, Innes A, Davis G, et al. Four-year outcomes from a multiparametric magnetic resonance imaging (MRI)-based active surveillance programme: PSA dynamics and serial MRI scans allow omission of protocol biopsies. BJU Int 2019;123:429-438 https://doi.org/10.1111/bju.14513
- Connor MJ, Miah S, Jayadevan R, Khoo CC, Eldred-Evans D, Shah T, et al. Value of systematic sampling in an mp-MRI targeted prostate biopsy strategy. Transl Androl Urol 2020;9:1501-1509 https://doi.org/10.21037/tau.2019.07.16
- Moore CM, Giganti F, Albertsen P, Allen C, Bangma C, Briganti A, et al. Reporting magnetic resonance imaging in men on active surveillance for prostate cancer: the PRECISE recommendations-a report of a European School of Oncology Task Force. Eur Urol 2017;71:648-655 https://doi.org/10.1016/j.eururo.2016.06.011
- Morgan VA, Riches SF, Thomas K, Vanas N, Parker C, Giles S, et al. Diffusion-weighted magnetic resonance imaging for monitoring prostate cancer progression in patients managed by active surveillance. Br J Radiol 2011;84:31-37 https://doi.org/10.1259/bjr/14556365
- Marin L, Ezziane M, Comperat E, Mozer P, Cancel-Tassin G, Cote JF, et al. Comparison of semi-automated and manual methods to measure the volume of prostate cancer on magnetic resonance imaging. Diagn Interv Imaging 2017;98:423-428 https://doi.org/10.1016/j.diii.2017.02.004
- Maggi M, Panebianco V, Mosca A, Salciccia S, Gentilucci A, Di Pierro G, et al. Prostate imaging reporting and data system 3 category cases at multiparametric magnetic resonance for prostate cancer: a systematic review and meta-analysis. Eur Urol Focus 2020;6:463-478 https://doi.org/10.1016/j.euf.2019.06.014
- Schoots IG. MRI in early prostate cancer detection: how to manage indeterminate or equivocal PI-RADS 3 lesions? Transl Androl Urol 2018;7:70-82 https://doi.org/10.21037/tau.2017.12.31
- Sonn GA, Fan RE, Ghanouni P, Wang NN, Brooks JD, Loening AM, et al. Prostate magnetic resonance imaging interpretation varies substantially across radiologists. Eur Urol Focus 2019;5:592-599 https://doi.org/10.1016/j.euf.2017.11.010
- Schlenker B, Apfelbeck M, Armbruster M, Chaloupka M, Stief CG, Clevert DA. Comparison of PIRADS 3 lesions with histopathological findings after MRI-fusion targeted biopsy of the prostate in a real world-setting. Clin Hemorheol Microcirc 2019;71:165-170 https://doi.org/10.3233/CH-189407
- Mendhiratta N, Meng X, Taneja SS. Using multiparametric MRI to 'personalize' biopsy for men. Curr Opin Urol 2015;25:498-503 https://doi.org/10.1097/MOU.0000000000000216
- Hansen NL, Koo BC, Warren AY, Kastner C, Barrett T. Sub-differentiating equivocal PI-RADS-3 lesions in multiparametric magnetic resonance imaging of the prostate to improve cancer detection. Eur J Radiol 2017;95:307-313 https://doi.org/10.1016/j.ejrad.2017.08.017
- Scialpi M, Martorana E, Aisa MC, Rondoni V, D'Andrea A, Bianchi G. Score 3 prostate lesions: a gray zone for PI-RADS v2. Turk J Urol 2017;43:237-240 https://doi.org/10.5152/tud.2017.01058
- Yaguchi G, Tang HJ, Deebajah M, Keeley J, Pantelic M, Williamson S, et al. The effect of multiplicity of PI-RADS 3 lesions on cancer detection rate of confirmatory targeted biopsy in patients diagnosed with prostate cancer and managed with active surveillance. Urol Oncol 2020;38:599.e9-599.e13 https://doi.org/10.1016/j.urolonc.2020.03.002
- Steinkohl F, Gruber L, Bektic J, Nagele U, Aigner F, Herrmann TRW, et al. Retrospective analysis of the development of PIRADS 3 lesions over time: when is a follow-up MRI reasonable? World J Urol 2018;36:367-373 https://doi.org/10.1007/s00345-017-2135-0
- Rais-Bahrami S, Turkbey B, Rastinehad AR, Walton-Diaz A, Hoang AN, Siddiqui MM, et al. Natural history of small index lesions suspicious for prostate cancer on multiparametric MRI: recommendations for interval imaging follow-up. Diagn Interv Radiol 2014;20:293-298 https://doi.org/10.5152/dir.2014.13319
- Schoots IG, Moore CM, Rouviere O. Role of MRI in low-risk prostate cancer: finding the wolf in sheep's clothing or the sheep in wolf's clothing? Curr Opin Urol 2017;27:238-245 https://doi.org/10.1097/MOU.0000000000000397